

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently amended): A pharmaceutical composition or a dietary supplement comprising at least 5% (w/w) of a triterpene fraction obtained from *Butyrospermum parkii* comprising:

- at least 2% (w/w) lupeol;
- at least 2% (w/w)  $\alpha$ -amyrin and/or  $\beta$ -amyrin; and
- at least 2% (w/w) butyrospermol;

wherein said triterpenes, lupeol,  $\alpha$ -amyrin,  $\beta$ -amyrin and/or butyrospermol [[,]] may be in the form of free alcohols or esters thereof;

and wherein said lupeol or said butyrospermol is in a weight percentage in the composition ranging from 5-90%.

2. (Currently amended): The pharmaceutical composition or a dietary supplement according to claim 1, wherein said triterpene fraction comprises:

- 10-40% (w/w) lupeol;
- 10-40% (w/w)  $\alpha$ -amyrin and/or  $\beta$ -amyrin; and
- 10-40% (w/w) butyrospermol,

wherein said triterpenes, lupeol,  $\alpha$ -amyrin,  $\beta$ -amyrin and/or butyrospermol, may be in the form of free alcohols or esters thereof. [[;]]

3. (Previously presented): The pharmaceutical composition or dietary supplement according to claim 1, further comprising a sterol fraction comprising at least one sterol selected from the group consisting of stigmasterol, avanasterol, 24-methyl-cholest-7-enol, karitesterol A, karitesterol B and  $\alpha$ -spinasterol, wherein said sterols may be in the form of free alcohols or esters thereof.
4. (Previously presented): The pharmaceutical composition or dietary supplement according to claim 1, wherein the triterpene fraction is in a weight percentage of at most 100% (w/w).
5. (Previously presented): The pharmaceutical composition or dietary supplement according to claim 3, wherein the ratio between the triterpene fraction and the sterol fraction is in the range of 1:100 to 500:1 (w/w).
6. (Previously presented): The pharmaceutical composition or dietary supplement according to claim 1, further comprising an extract of *Calendula officinalis*.
7. (Previously presented): The pharmaceutical composition according to claim 1 formulated for systemic administration.
8. (Previously presented): The pharmaceutical composition according to claim 1 formulated for topical administration.
9. (Previously presented): The pharmaceutical composition according to claim 8, wherein the pharmaceutical composition is formulated as a fluid, ointment, gel, liniment, emulsion or spray (e.g. aerosol).
10. (Withdrawn): The use of a composition according to claim 1 for the preparation of a medicament or a dietary supplement for immunomodulation in a mammal.

11. (Withdrawn): The use of a composition claim 1 for the preparation of a medicament or a dietary supplement for the suppression of hypersensitivity and/or inflammatory reaction in a mammal.

12. (Withdrawn): The use of a composition according to claim 11 for the preparation of a medicament for the treatment or prevention of inflammation or hypersensitivity of the skin or mucous membranes in a mammal.

13. (Withdrawn): The use according to claim 11 for the preparation of a medicament or a dietary supplement for the treatment or prevention of autoimmune disease and/or chronic inflammatory disease in a mammal.

14. (Withdrawn): The use according to claim 13 for the preparation of a medicament or a dietary supplement for the treatment or prevention of psoriasis, atopic dermatitis, contact dermatitis, Crohn's disease, ulcerative colitis, rheumatoid arthritis or osteoarthritis in a mammal.

15. (Withdrawn): The use of a composition according to claim 1 for the preparation of a medicament or a dietary supplement for the alleviation of pain in a mammal.

16. (Withdrawn): The use of a composition according to claim 1 for the preparation of a medicament or a dietary supplement for the treatment or prevention of prostatitis and/or benign prostatic hypertrophy.

17. (Currently amended): A method for treating hypersensitivity or inflammation in a mammal, ~~characterised by comprising~~ administering a composition comprising at least 5% (w/w) of a triterpene fraction obtained from *Butyrospermum parkii*, ~~wherein the triterpene fraction comprises~~ comprising:

- at least 2% (w/w) lupeol;
- at least 2% (w/w)  $\alpha$ -amyrin and/or  $\beta$ -amyrin; and

- at least 2% (w/w) butyrospermol;

wherein said triterpenes, lupeol,  $\alpha$ -amyrin,  $\beta$ -amyrin and/or butyrospermol, may be in the form of free alcohols or esters thereof.

18. (Previously presented): The method according to claim 17, wherein the treating of hypersensitivity or inflammation is for the treating of hypersensitivity of the skin or mucous membranes of a mammal.

19. (Withdrawn): A method for the treatment or prevention of an autoimmune disorder and/or a chronic inflammatory disorder in a mammal, characterised by administering a mixture according to claim 1 to said mammal.

20. (Withdrawn): A method for the treatment or prevention of psoriasis, atopic eczema, contact dermatitis, Crohn's disease, ulcerative colitis, rheumatoid arthritis and/or osteoarthritis in a mammal, characterised by administering a mixture according to claim 1 to said mammal.

21. (Withdrawn): A method for the treatment or prevention of pain in a mammal, characterised by administering a mixture according to claim 1 to said mammal.

22. (Withdrawn): A method for the treatment or prevention of prostatitis or benign prostatic hypertrophy in a mammal, characterised by administering a mixture according to claim 1 to said mammal.

23. (Withdrawn): A method for the preparation of a composition according to claim 1, characterised by obtaining an extract or a concentrate of *Butyrospermum parkii*, said extract or concentrate containing at least 5% (w/w) of a Butyrospermum-triterpene fraction comprising:

- at least 2% (w/w) lupeol;

- at least 2% (w/w)  $\alpha$ -amyrin and/or  $\beta$ -amyrin;

- at least 2% (w/w) butyrospermol; and

- optionally at least 1% germanicol, dammaradienol, 24-methylene-dammarenol and/or parkeol,

wherein said triterpenes may be in the form of free alcohols or esters thereof, especially cinnamic acid, acetic acid or fatty acid esters; and

24. (Withdrawn): A method according to claim 23 wherein the extract or concentrate of *Butyrospermum parkii* further comprises a sterol fraction comprising at least one sterol selected from the group consisting of stigmasterol, avanasterol, 24-methyl-cholest-7-enol, karitesterol A, karitesterol B and  $\alpha$ -spinasterol, wherein said sterols may be in the form of free alcohols or esters thereof, especially cinnamic acid, acetic acid or fatty acid esters.

25. (Withdrawn): A method according to claim 23 wherein said extract or concentrate of *Butyrospermum parkii* is further mixed with a pharmaceutically acceptable carrier.

26. (Previously presented): The pharmaceutical composition or dietary supplement according to claim 1, further comprising a pharmaceutically acceptable carrier.

27. (Currently amended): The pharmaceutical composition or dietary supplement according to claim 1, further comprising at least 1% (w/w) of a fraction comprising at least one chemical selected from the group consisting of germanicol, dammaradienol, 24-methylene-dammarenol and and/or parkeol. [[,]]

28. (Previously presented): The pharmaceutical composition or dietary supplement according to claim 1, wherein said esters are selected from the group consisting of cinnamic acid esters, acetic acid esters and fatty acid esters.

29. (Currently amended): The pharmaceutical composition or dietary supplement according to claim 1, further comprising at least 2-30% (w/w) of a fraction comprising at least one chemical selected from the group consisting of germanicol, dammaradienol, 24-methylene-dammarenol and and/or parkeol. [[,]]

30. (Previously presented): The pharmaceutical composition or dietary supplement according to claim 3, wherein said esters are selected from the group consisting of cinnamic acid esters, acetic acid esters and fatty acid esters.

31. (Previously presented): The pharmaceutical composition or dietary supplement according to claim 3, wherein the triterpene fraction together with the sterol fraction is in a weight percentage of at most 100% (w/w).

32. (Previously presented): The pharmaceutical composition or dietary supplement according to claim 1, wherein the triterpene fraction is derived from the fruit, leaves, stem, bark or root of *Butyrospermum parkii*.

33. (Previously presented): The pharmaceutical composition or dietary supplement according to claim 32, wherein the triterpene fraction is derived from the fruit of *Butyrospermum parkii*.

34. (Previously presented): The method according to claim 17, wherein said triterpene fraction is in a composition as defined in any one of claims 1 to 9, 26 to 33 and 35 to 38.

35. (Previously presented): The pharmaceutical composition or dietary supplement according to claim 1, wherein said butyrospermol is in a weight percentage in the composition ranging from 8-40 %.

36. (Previously presented): The pharmaceutical composition or dietary supplement according to claim 1, wherein said butyrospermol is in a weight percentage in the composition ranging from 9-40 %.

37. (Previously presented): The pharmaceutical composition or dietary supplement according to claim 1, wherein said lupeol is in a weight percentage in the composition ranging from 7-40 %.

38. (Previously presented): The pharmaceutical composition or dietary supplement according to claim 1, wherein said lupeol is in a weight percentage in the composition ranging from 8-40 %.